British women may be at risk from PIP implants sold under a different name

06 | 01 | 12

Bookmark and Share

It has emerged that thousands more women may be at risk following an announcement, which found that the implants made by Poly Implant Prothese (PIP) have also been sold by Dutch manufacturer Rofil.

The faulty PIP implants are the subject of a Medical Device Alert (MDA) by the Medicines and Healthcare products Regulatory Agency (MHRA), with a recall being issued on March 31 2010 for all UK implants. The implants were recalled following concerns relating to an increase in rupture rates in these implants.

The failure rate for UK patients has been defined by the MHRA as being 1%, whereas French authorities have found that the implants have a 5% rupture rate and a major UK private clinic has reported that the failure rate amongst its patients is at 7%.

Whilst the Rofil implant was not sold in British clinics, it’s estimated that more than 5000 British woman may have the implant following cut-price surgery abroad in countries such as Belgium, Poland and the Czech Republic.

Rofil, the Dutch implant manufacturer is believed to have had a long-standing agreement to buy implants from PIP, which were rebranded as M-implants.

Women all over the UK affected by the PIP breast implant recall are awaiting a statement from the Government on the PIP breast implant scandal, with a decision imminent.

Mark Harvey, Partner and Head of Litigation at Hugh James solicitors is representing over 600 women with PIP implants of which over 300 have contacted Hugh James in the last two weeks.

View our PIP news articles archive

For information on joining the group represented by Mark Harvey please contact Hugh James on 02920 224 871 or complete the enquiry form.

Design by Brand 68 | Development by Fusionworkshop | SEO by Pinnacle Internet Marketing